Skip to main content

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

Trial Status: Active

To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL / SLL, as measured by progression free survival.

Inclusion Criteria

  • Unsuitable for chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR)
  • Confirmed diagnosis of CD20-positive CLL or SLL, requiring treatment.
  • Measurable disease by imaging
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
  • Life expectancy ≥ 6 months.
  • Adequate bone marrow function.
  • Adequate renal and hepatic function.

Exclusion Criteria

  • Previous systemic treatment for CLL/SLL.
  • Requires ongoing need for corticosteroid treatment.
  • Known prolymphocytic leukemia or history of or suspected Richter's transformation.
  • Clinically significant cardiovascular disease.
  • Prior malignancy within the past 3 years, except for curatively treated basal or squamous cell skin cancer, non-muscle-invasive bladder cancer, carcinoma in situ of the cervix of breast, or localized Gleason score 6 prostate cancer.
  • History of severe bleeding disorder.
  • History of stroke or intracranial hemorrhage within 6 months before the first dose of study drug.
  • Severe or debilitating pulmonary disease.
  • Inability to swallow capsules or disease affecting gastrointestinal function.
  • Active infection requiring systemic treatment.
  • Known central nervous system involvement by leukemia or lymphoma
  • Underlying medical condition that will render the administration of study drug hazardous or obscure interpretation of toxicity or AEs
  • Known infection with human immunodeficiency virus (HIV) or active hepatitis B or C infection.
  • Major surgery ≤ 4 weeks prior to start of study treatment.
  • Pregnant or nursing females.
  • Vaccination with live vaccine within 35 days prior to the first dose of study drug.
  • Ongoing alcohol or drug addiction
  • Known hypersensitivity to zanubrutinib, bendamustine, rituximab, or venetoclax (as applicable) or any other ingredients of the study drugs.
  • Requires ongoing treatment with strong cytochrome P450 (CYP3A) inhibitor or inducer.
  • Concurrent participation in another therapeutic clinical trial.

Georgia

Atlanta
Emory University Hospital / Winship Cancer Institute
Status: CLOSED_TO_ACCRUAL_AND_INTERVENTION

Illinois

Chicago
Northwestern University
Status: ACTIVE

Massachusetts

Boston
Brigham and Women's Hospital
Status: ACTIVE
Dana-Farber Cancer Institute
Status: ACTIVE

Missouri

Saint Louis
Siteman Cancer Center at Washington University
Status: CLOSED_TO_ACCRUAL

New York

New York
Icahn School of Medicine at Mount Sinai
Status: CLOSED_TO_ACCRUAL
Memorial Sloan Kettering Cancer Center
Status: WITHDRAWN
NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center
Status: ACTIVE

North Carolina

Durham
Duke University Medical Center
Status: ACTIVE

Oregon

Portland
OHSU Knight Cancer Institute
Status: ACTIVE

Virginia

Charlottesville
University of Virginia Cancer Center
Status: ACTIVE

Washington

Seattle
Fred Hutch / University of Washington Cancer Consortium
Status: ACTIVE

This is a global phase 3, open label, randomized study of zanubrutinib versus bendamustine

plus rituximab (B+R) in participants with previously untreated chronic lymphocytic leukemia

or small lymphocytic lymphoma (CLL/SLL), including participants without del(17p) [Cohort 1]

and participants with del(17p) [Cohort 2 and Cohort 3]. Participants in Cohort 1 are

randomized 1:1 to zanubrutinib (Arm A) or bendamustine plus rituximab (Arm B). Randomization

will be stratified by age, Binet stage, immunoglobulin variable region heavy chain (IGHV)

mutational status, and geographic region. Participants in Cohort 2 will receive treatment

with zanubrutinib. Participants in Cohort 3 will receive treatment with zanubrutinib and

venetoclax.

Trial Phase Phase III

Trial Type Treatment

Lead Organization
BeiGene

  • Primary ID BGB-3111-304
  • Secondary IDs NCI-2017-02160, 2017-001551-31, CTR20190416, BGB-3111-304 (Sequoia)
  • Clinicaltrials.gov ID NCT03336333